[go: up one dir, main page]

DE60007310D1 - Zusammensetzungen und methoden zur verhinderung des zelltods - Google Patents

Zusammensetzungen und methoden zur verhinderung des zelltods

Info

Publication number
DE60007310D1
DE60007310D1 DE60007310T DE60007310T DE60007310D1 DE 60007310 D1 DE60007310 D1 DE 60007310D1 DE 60007310 T DE60007310 T DE 60007310T DE 60007310 T DE60007310 T DE 60007310T DE 60007310 D1 DE60007310 D1 DE 60007310D1
Authority
DE
Germany
Prior art keywords
cell death
compositions
methods
prevent cell
neurodegeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60007310T
Other languages
English (en)
Inventor
M Bitler
L Wood
T Anstine
Anke Meyer-Franke
Qi Zhao
A Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perrigo Pharma International DAC
Original Assignee
Elan Pharma International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd filed Critical Elan Pharma International Ltd
Application granted granted Critical
Publication of DE60007310D1 publication Critical patent/DE60007310D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/10—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60007310T 1999-06-04 2000-06-02 Zusammensetzungen und methoden zur verhinderung des zelltods Expired - Lifetime DE60007310D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13761899P 1999-06-04 1999-06-04
US13885599P 1999-06-11 1999-06-11
US16825699P 1999-11-30 1999-11-30
PCT/US2000/015181 WO2000075117A1 (en) 1999-06-04 2000-06-02 Compositions and methods for inhibiting cell death

Publications (1)

Publication Number Publication Date
DE60007310D1 true DE60007310D1 (de) 2004-01-29

Family

ID=27385047

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60007310T Expired - Lifetime DE60007310D1 (de) 1999-06-04 2000-06-02 Zusammensetzungen und methoden zur verhinderung des zelltods

Country Status (8)

Country Link
US (1) US6541486B1 (de)
EP (1) EP1189889B1 (de)
JP (1) JP2003501418A (de)
AT (1) ATE256666T1 (de)
AU (1) AU5314900A (de)
CA (1) CA2375843A1 (de)
DE (1) DE60007310D1 (de)
WO (1) WO2000075117A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072862A1 (en) * 1999-06-04 2004-04-15 Bitler Catherine M. Compositions for treating ischemia-related neuronal damage
CN1615873A (zh) 1999-12-24 2005-05-18 阿文蒂斯药物有限公司 氮杂吲哚类化合物
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP1465882B1 (de) * 2001-12-21 2011-08-24 X-Ceptor Therapeutics, Inc. Heterocyclische modulatoren von nukleären rezeptoren
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US20040234860A1 (en) * 2003-05-23 2004-11-25 Deyang Qu Alkaline electrochemical cell having modified graphite additive
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
KR20090021169A (ko) * 2006-05-16 2009-02-27 크놉 뉴로사이언시스 인코포레이티드 Ｒ(+) 및 ｓ(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) * 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2010148409A1 (en) * 2009-06-19 2010-12-23 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3038467B1 (de) 2013-08-13 2020-07-29 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von plasmazellenerkrankungen und prolymphozytischen b-zellen-erkrankungen
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US11427569B2 (en) * 2019-02-15 2022-08-30 Wisconsin Alumni Research Foundation Benzoimidazole indolyl methanes and methods of using them to inhibit PCKS9 and PCKS9-mediated ailments
TW202140477A (zh) 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337578A (en) * 1961-09-15 1967-08-22 Heidenheimer Chemisches Lab 2, 2'-alkylenebisbenzimidazoles
US3337579A (en) 1961-09-15 1967-08-22 Upjohn Co Unsymmetrical 2, 2'-alkylene-bisbenzimidazoles
US3105837A (en) 1961-10-20 1963-10-01 Upjohn Co 2, 2'-alkylenebisbenzimidazoles
US3808005A (en) 1968-02-22 1974-04-30 Agfa Gevaert Nv Silver halide emulsion stabilized with a bidentate heterocyclic compound containing a sulpho or a carboxyl group
DE1952253C3 (de) * 1968-10-22 1979-03-22 Fuji Photo Film Co., Ltd., Ashigara, Kanagawa (Japan) Verfahren zum Entwickeln farbphotographischer Aufzeichnungsmaterialien
DE2051023A1 (en) * 1970-10-17 1972-04-20 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Mono and dis-azo dyes - of the benzimidazole series contg sulphonic acid gps
FR2115374A1 (en) * 1970-11-25 1972-07-07 Merck & Co Inc (tri) methylene - and vinylene-bis-benzimidazoles - with antiviral ac
BE793407A (fr) 1971-12-28 1973-06-28 Hoechst Ag Imidazolyl - (2) -carbinols ayant une activite hypolipidemique et leur procede de preparation
CH593954A5 (de) * 1975-07-21 1977-12-30 Ciba Geigy Ag
DE2651580A1 (de) * 1976-11-12 1978-06-22 Hoechst Ag Neue imidazolverbindungen, verfahren zu deren herstellung und diese enthaltende arzneimittel
US4228177A (en) * 1979-08-08 1980-10-14 E. R. Squibb & Sons, Inc. 2,3-Dihydro-3-(1H-imidazol-1-ylmethylene)-4H-1-benzothiopyran-4-ones
US4324794A (en) 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
US5147863A (en) 1985-11-25 1992-09-15 Merrell Dow Pharmaceuticals Inc. 2,2'-bi-1H-imidazoles
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
US4835085A (en) 1986-10-17 1989-05-30 Ciba-Geigy Corporation 1,2-Naphthoquinone diazide sulfonyl ester compound with linking benzotriazole groups and light-sensitive composition with compound
US4981613A (en) 1986-11-04 1991-01-01 Fuji Photo Film Co., Ltd. Laser light source
US4940723A (en) 1988-10-20 1990-07-10 University Of North Carolina, Chapel Hill Use of bis-(5-amidino-2-benzimidazolyl) methane (BABIM) to treat arthritis
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
JPH05291729A (ja) 1992-04-07 1993-11-05 Hideaki Yamaguchi 銅スルーホールプリント配線板の製造方法
JPH05287562A (ja) 1992-04-07 1993-11-02 Hideaki Yamaguchi 金属の表面処理方法
US5387600A (en) 1992-07-30 1995-02-07 Fuji Photo Film Co., Ltd. Treating arteriosclerosis using benzimidazole compositions
US5428051A (en) 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
IL111011A0 (en) * 1993-09-22 1994-11-28 Wellcome Found Bisbenzimidazole compounds, their preparation and pharmaceutical compositions containing them
US6815461B1 (en) * 1994-01-20 2004-11-09 The University Of North Carolina At Chapel Hill Method of inhibiting retroviral integrase
DE59509233D1 (de) 1994-02-24 2001-06-13 Haarmann & Reimer Gmbh Kosmetische und dermatologische zubereitungen, enthaltend phenylen-1,4-bisbenzimidiazolesulfonsäuren
US5693515A (en) 1995-04-28 1997-12-02 Arris Pharmaceutical Corporation Metal complexed serine protease inhibitors
US6255091B1 (en) 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
DE19517448A1 (de) * 1995-05-12 1996-11-14 Thomae Gmbh Dr K Neue Benzothiazole und Benzoxazole, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
DE19648010A1 (de) * 1996-11-20 1998-05-28 Haarmann & Reimer Gmbh Verwendung von substituierten Benzazolen als UV-Absorber, neue Benzazole und Verfahren zu ihrer Herstellung
EE04055B1 (et) * 1997-04-07 2003-06-16 Axys Pharmaceuticals, Inc. Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks, ja nende kasutamine
EP1030844A1 (de) * 1997-11-10 2000-08-30 Array Biopharma Inc. Verbindungen, die die aktivität von tryptase hemmen
WO1999026932A1 (en) * 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. By amidino group substituted heterocyclic derivatives and their use as anticoagulants
AU2548699A (en) * 1998-02-23 1999-09-06 Rei Asakai Cell death inhibitors

Also Published As

Publication number Publication date
EP1189889B1 (de) 2003-12-17
EP1189889A1 (de) 2002-03-27
WO2000075117A1 (en) 2000-12-14
CA2375843A1 (en) 2000-12-14
AU5314900A (en) 2000-12-28
US6541486B1 (en) 2003-04-01
JP2003501418A (ja) 2003-01-14
ATE256666T1 (de) 2004-01-15

Similar Documents

Publication Publication Date Title
DE60007310D1 (de) Zusammensetzungen und methoden zur verhinderung des zelltods
WO2008128038A3 (en) Methods and compositions for treating cardiac dysfunctions
WO2006103037A3 (de) ZUSAMMENSETZUNG ENTHALTEND β-DEFENSIN 2
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EP3081214A3 (de) Zellnekrosehemmer
MX2007005590A (es) Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas.
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
YU23102A (sh) Jedinjenja za lečenje ishemije
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
CL2007001734A1 (es) Compuestos derivados de imidazol condensados con heterociclos nitrogenados; composicion farmaceutica; y uso para tratar o prevenir la enfermedad de alzheimer, demencia senil y demencia asociada con enfermedad de parkinson entre otras.
UA105018C2 (uk) Акриламідопохідні, застосовні як інгібітори переходу мітохондріальної проникності
MY143795A (en) Tetrahydropyridoindole derivatives
WO2004046345A3 (en) Use of hmgb fragments as anti-inflammatory agents
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
WO2005051914A8 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
CL2007003332A1 (es) Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
IL188092A0 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
UY30629A1 (es) Nuevo péptido de actinomadura namibiensis
WO2000020025A3 (en) Akt compositions for enhancing survival of cells
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
CL2008003183A1 (es) Compuestos derivados de triazol pirrolidina; composicion farmaceutica de dichos compuestos; combinacion farmaceutica; y su uso en el tratamiento o prevencion de enfermedades tales como reflujo gastroesofagico, dolor, ansiedad, sindrome de intestino irritable entre otras.
WO2005017160A3 (en) Mobilization of hematopoietic cells
ATE486567T1 (de) Orale zusammensetzung mit einer ersten zusammensetzung (a) und einer zweiten zusammensetzung (b) zur verwendung als gemische zur getrennten oder aufeinanderfolgenden verwendung in der kosmetischen behandlung des menschlichen körpers
TW200621773A (en) Bicyclononene derivatives

Legal Events

Date Code Title Description
8332 No legal effect for de